Building Better Medicines Together for Patients

Mission

At SalubrisBio we have passion, commitment, and enthusiasm for innovative drug discovery and development. We embrace challenges and value teamwork to solve problems and achieve our ambitions.

We are the first company in the world to bring a bispecific antibody fusion protein into clinical trials in a cardiovascular indication.  We endeavor to make this the first of many global innovation achievements.

Who we are

Sam Murphy

Chief Executive Officer

Sam Murphy

Sam Murphy

Chief Executive Officer

Sam has worked at Salubris for over four years – joining the company as VP and Head of International Business Development, and subsequently taking an additional role as Chief Business Officer. Prior to joining Salubris, Sam worked for more than ten years in strategy consulting and transaction advisory services across several global firms, most recently as a Senior Principal at IMS (now IQVIA). Sam’s commercial strategy engagements encompassed 18 of the top 25 pharmaceutical companies, as well as numerous small and mid-sized biotech companies, with an emphasis on business development and market access. Sam completed his PhD in Virology at the University of Pennsylvania and his Post-Doctoral Fellowship in Gene Therapy and Translational Medicine at Children’s Hospital of Philadelphia. Sam currently also serves as Chairman of the Board at GO Therapeutics, Board Director at MedAlliance SA and Viracta Therapeutics, and a Board Observer at Mercator Medsystems. He is an author of >20 peer-reviewed publications and an inventor on several issued patents.


Research Focus

We focus exclusively on the development of novel, complex biologic therapeutics which will provide clinically meaningful improvements in disease burden and quality of life to patients with significant medical needs.

We work in the areas of cardiovascular disease and oncology. Together, these disease areas represent the two leading causes of death in the US today.

US Leading Causes of Death (2017)

US Leading Causes of Death (2017)

Pipeline Overview

Pipeline Overview

History

SalubrisBio was founded in August 2016 as a wholly-owned subsidiary of the China-based pharmaceutical company Salubris Pharmaceuticals Co. Ltd. (www.salubris.com). SalubrisBio is an innovation-focused biotech with pioneering research and development programs. Headquartered in the US, SalubrisBio reflects Salubris Pharmaceuticals’ commitment to innovation and expansion into the global market, and retains the core philosophy of developing therapeutics for large patient populations with significant unmet needs.